Skip to content
You are now leaving to visit

Ionis Pharmaceuticals Announces the Initiation of a Clinical Study of its First Orally Delivered Antisense Drug for the Treatment of Gastrointestinal Disorders

– Ionis Earns $5 Million Milestone Payment from Janssen CARLSBAD, Calif. , Dec. 21, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has earned a $5 million milestone payment associated with initiation and enrollment in a newly initiated Phase 1 clinical study